エドガーで原本を確認する
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
February 1, 2024
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
| Form 20-F [X] | Form 40-F [ ] |
Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 1 February 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
|
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 8 / 2024 | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Liselotte Sofie Hyveled | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Member of the Board of Directors | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) |
|||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 2,028 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
2,028 shares DKK 0.00 |
|||
| e) | Date of the transaction | 2024-01-31 | |||
| f) | Place of the transaction | Outside a trading venue | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 8 / 2024 | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Liselotte Sofie Hyveled | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Member of the Board of Directors | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) |
|||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 2,042 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
2,042 shares DKK 0.00 |
|||
| e) | Date of the transaction | 2024-01-31 | |||
| f) | Place of the transaction | Outside a trading venue | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 8 / 2024 | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | President and CEO | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) |
|||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 131,760 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
131,760 shares DKK 0.00 |
|||
| e) | Date of the transaction | 2024-01-31 | |||
| f) | Place of the transaction | Outside a trading venue | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 8 / 2024 | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | President and CEO | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) |
|||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 149,422 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
149,422 shares DKK 0.00 |
|||
| e) | Date of the transaction | 2024-01-31 | |||
| f) | Place of the transaction | Outside a trading venue | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 8 / 2024 | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Maziar Mike Doustdar | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) |
|||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 41,488 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
41,488 shares DKK 0.00 |
|||
| e) | Date of the transaction | 2024-01-31 | |||
| f) | Place of the transaction | Outside a trading venue | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 8 / 2024 | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Maziar Mike Doustdar | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) |
|||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 48,791 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
48,791 shares DKK 0.00 |
|||
| e) | Date of the transaction | 2024-01-31 | |||
| f) | Place of the transaction | Outside a trading venue | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 8 / 2024 | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Maziar Mike Doustdar | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Sale of shares | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 756.84 | 2,166 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
2,166 shares DKK 756.84 |
|||
| e) | Date of the transaction | 2024-01-31 | |||
| f) | Place of the transaction | Nasdaq Copenhagen | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 8 / 2024 | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Maziar Mike Doustdar | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Sale of shares | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 756.84 | 2,548 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
2,548 shares DKK 756.84 |
|||
| e) | Date of the transaction | 2024-01-31 | |||
| f) | Place of the transaction | Nasdaq Copenhagen | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 8 / 2024 | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Ludovic Helfgott | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) |
|||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 37,346 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
37,346 shares DKK 0.00 |
|||
| e) | Date of the transaction | 2024-01-31 | |||
| f) | Place of the transaction | Outside a trading venue | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 8 / 2024 | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Ludovic Helfgott | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) |
|||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 36,664 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
36,664 shares DKK 0.00 |
|||
| e) | Date of the transaction | 2024-01-31 | |||
| f) | Place of the transaction | Outside a trading venue | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 8 / 2024 | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Ludovic Helfgott | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Sale of shares | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 756.84 | 11,620 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
11,620 shares DKK 756.84 |
|||
| e) | Date of the transaction | 2024-01-31 | |||
| f) | Place of the transaction | Nasdaq Copenhagen | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 8 / 2024 | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Ludovic Helfgott | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Sale of shares | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 756.84 | 11,407 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
11,407 shares DKK 756.84 |
|||
| e) | Date of the transaction | 2024-01-31 | |||
| f) | Place of the transaction | Nasdaq Copenhagen | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 8 / 2024 | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Karsten Munk Knudsen | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) |
|||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 41,254 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
41,254 shares DKK 0.00 |
|||
| e) | Date of the transaction | 2024-01-31 | |||
| f) | Place of the transaction | Outside a trading venue | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 8 / 2024 | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Karsten Munk Knudsen | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) |
|||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 43,402 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
43,402 shares DKK 0.00 |
|||
| e) | Date of the transaction | 2024-01-31 | |||
| f) | Place of the transaction | Outside a trading venue | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 8 / 2024 | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Douglas Langa | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) |
|||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 41,488 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
41,488 shares DKK 0.00 |
|||
| e) | Date of the transaction | 2024-01-31 | |||
| f) | Place of the transaction | Outside a trading venue | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 8 / 2024 | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Douglas Langa | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction |
Other transaction (transfer of shares in accordance with Long Term Incentive programme) |
|||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 39,755 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
39,755 shares DKK 0.00 |
|||
| e) | Date of the transaction | 2024-01-31 | |||
| f) | Place of the transaction | Outside a trading venue | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 8 / 2024 | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Douglas Langa | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Sale of shares | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 756.84 | 22,027 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
22,027 shares DKK 756.84 |
|||
| e) | Date of the transaction | 2024-01-31 | |||
| f) | Place of the transaction | Nasdaq Copenhagen | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 8 / 2024 | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Douglas Langa | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Sale of shares | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 756.84 | 19,878 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
19,878 shares DKK 756.84 |
|||
| e) | Date of the transaction | 2024-01-31 | |||
| f) | Place of the transaction | Nasdaq Copenhagen | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 8 / 2024 | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Douglas Langa | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President, head of North America Operations | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
ADRs | |||
| Identification code | NVO | ||||
| b) | Nature of the transaction | Purchase of ADRs | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 1,092.25 | 16.31 ADRs | ||||
| d) |
Aggregated information · Aggregated volume · Price |
16.31 ADRs DKK 1,092.25 |
|||
| e) | Date of the transaction | 2023-04-10 | |||
| f) | Place of the transaction | New York Stock Exchange | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 8 / 2024 | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Douglas Langa | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President, head of North America Operations | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
ADRs | |||
| Identification code | NVO | ||||
| b) | Nature of the transaction | Purchase of ADRs | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 1,275.49 | 10.42 ADRs | ||||
| d) |
Aggregated information · Aggregated volume · Price |
10.42 ADRs DKK 1,275.49 |
|||
| e) | Date of the transaction | 2023-09-01 | |||
| f) | Place of the transaction | New York Stock Exchange | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 8 / 2024 | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Martin Holst Lange | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) |
|||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 16,780 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
16,780 shares DKK 0.00 |
|||
| e) | Date of the transaction | 2024-01-31 | |||
| f) | Place of the transaction | Outside a trading venue | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 8 / 2024 | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Martin Holst Lange | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) |
|||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 33,600 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
33,600 shares DKK 0.00 |
|||
| e) | Date of the transaction | 2024-01-31 | |||
| f) | Place of the transaction | Outside a trading venue | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 8 / 2024 | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Tania Sabroe | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) |
|||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 7,763 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
7,763 shares DKK 0.00 |
|||
| e) | Date of the transaction | 2024-01-31 | |||
| f) | Place of the transaction | Outside a trading venue | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 8 / 2024 | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Tania Sabroe | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) |
|||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 13,220 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
13,220 shares DKK 0.00 |
|||
| e) | Date of the transaction | 2024-01-31 | |||
| f) | Place of the transaction | Outside a trading venue | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 8 / 2024 | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Tania Sabroe | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Sale of shares | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 756.84 | 413 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
413 shares DKK 756.84 |
|||
| e) | Date of the transaction | 2024-01-31 | |||
| f) | Place of the transaction | Nasdaq Copenhagen | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 8 / 2024 | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Tania Sabroe | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Sale of shares | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 756.84 | 702 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
702 shares DKK 756.84 |
|||
| e) | Date of the transaction | 2024-01-31 | |||
| f) | Place of the transaction | Nasdaq Copenhagen | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 8 / 2024 | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Marcus Schindler | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) |
|||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 16,780 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
16,780 shares DKK 0.00 |
|||
| e) | Date of the transaction | 2024-01-31 | |||
| f) | Place of the transaction | Outside a trading venue | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 8 / 2024 | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Marcus Schindler | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) |
|||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 33,600 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
33,600 shares DKK 0.00 |
|||
| e) | Date of the transaction | 2024-01-31 | |||
| f) | Place of the transaction | Outside a trading venue | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 8 / 2024 | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Camilla Sylvest | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) |
|||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 41,254 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
41,254 shares DKK 0.00 |
|||
| e) | Date of the transaction | 2024-01-31 | |||
| f) | Place of the transaction | Outside a trading venue | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 8 / 2024 | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Camilla Sylvest | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) |
|||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 43,402 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
43,402 shares DKK 0.00 |
|||
| e) | Date of the transaction | 2024-01-31 | |||
| f) | Place of the transaction | Outside a trading venue | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 8 / 2024 | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Henrik Ehlers Wulff | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) |
|||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 43,563 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
43,563 shares DKK 0.00 |
|||
| e) | Date of the transaction | 2024-01-31 | |||
| f) | Place of the transaction | Outside a trading venue | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 8 / 2024 | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Henrik Ehlers Wulff | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) |
|||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 45,834 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
45,834 shares DKK 0.00 |
|||
| e) | Date of the transaction | 2024-01-31 | |||
| f) | Place of the transaction | Outside a trading venue | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 8 / 2024 | |||
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 63,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Media: | |
|
Ambre James-Brown +45 3079 9289 abmo@novonordisk.com |
Elizabeth DeLuca (US) +1 609 580 9868 edel@novonordisk.com |
| Investors: | |
|
Daniel Muusmann Bohsen +45 3075 2175 dabo@novonordisk.com |
Frederik Taylor Pitter +45 3075 8259 fptr@novonordisk.com |
|
David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com |
Mark Joseph Root (US) +1 848 213 3219 mjhr@novonordisk.com |
|
Sina Meyer +45 3079 6656 azey@novonordisk.com |
|
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 8 / 2024 | |||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: February 1, 2024 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen Chief Executive Officer |